AzTrials
AzTrials

GliomaGLIO-RADNCT06036381

Spatial and Temporal Characterization of Gliomas Using Radiomic Analysis

An observational study of Glioma, run by Tata Memorial Centre at 1 site in India.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Glioma are type of primary brain tumors arising within the substance of brain. Different type of gliomas are seen which are classified depending upon pathological examination and advanced molecular techniques, which help to determine the aggressiveness of the tumor and outcomes. Read more about this study

Who is it for?
Ages 1 year and older
Conditions the study is for
Glioma
What is being tested?
Radiomic analysis of imaging - MRI, PET, CT
How many people
1,000 participants
Where
1 siteIndia
Study dates
15 Feb 2024to Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 1 year and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Study population will be according to the Inclusion and Exclusion Criteria . Study Includes vulnerable participants also. Minors (up to 18 years),Elderly

Who may be able to join

  • Patients with glioma or glioma-mimicking pathology with imaging available in TMC between January 2010 and December 2022.

Who cannot join

  • Imaging done outside TMC.
  • Motion artifacts or other artifacts causing image degradation.
  • Size of tumor or region of interest < 1 cm in the largest dimension

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Dr. ARCHYA DASGUPTA, MD contact

022-24177000 ext. 6861

archya1010@gmail.com

India1 site, 1 recruiting
  • Tata Memorial Hospital

    Mumbai, Maharashtra, 400012

    Dr Archya Dasgupta, MD

    Recruiting

Other trials in India

About this study

Glioma are type of primary brain tumors arising within the substance of brain. Different type of gliomas are seen which are classified depending upon pathological examination and advanced molecular techniques, which help to determine the aggressiveness of the tumor and outcomes. Artificial intelligence uses advanced analytical process aided by computer which can be undertaken on the medical images. We plan to use artificial intelligence techniques to identify the abnormal areas within the brain representing tumor from the radiological images. Also, similar approach will be undertaken to classify gliomas with good or bad prognosis, to differentiate glioma from other type of brain tumors, and to detect response after treatment.

Read the detailed description

In the proposed retrospective study, images (MRI, CT, or PET) undertaken as part of standard of care (pre-treatment, post-operative, response assessment, and surveillance) will be analyzed. The DMG database maintaining records of patients registered in TMC neuro-oncology DMG will be screened to identify the patients eligible for the study. With approximately 500-600 gliomas seen annually and approximately 80-100 patients/year having pre-treatment imaging, we expect a ceiling of 1000 patients during 2010-2022, which will be the maximum number of patients used for the analysis. All the images will be downloaded from the PACS applying anonymization filters, with clinical records extracted by review of electronic medical records and radiation plans. Imaging pre-processing will be done, which will include skull stripping and registration across different modalities (e.g., MRI and CT) or different sequences (e.g., T1C, T2W, ADC) will be done using rigid or deformable algorithms as suited best for the modality. Image segmentation to classify the region of interest will be done and verified individually by a neuro-radiologist or nuclear medicine physician as appropriate. The segmentations will be done to identify T1-contrast enhancing region (CE), non-enhancing regions (NE), and necrosis (NEC) guided by T1-C, T2W, and T2-FLAIR areas. The contours and the images will be resampled to a uniform resolution for different sequences or modalities (e.g., T2W/ ADC/ PET) to match either with the 3D sequence (e.g., FSPGR sequence) or available images with the least slice thickness. Subsequently, normalization techniques (e.g., histogram normalization/ Z-score normalization) will be undertaken within the individual images and across the entire dataset to account or image heterogeneity, including field strength for MRI and different image acquisition parameters. For auto segmentation, both supervised and unsupervised machine learning algorithms will be applied. For the supervised model, the entire database will be split into training and test cohorts for the model and application development, respectively. The effectiveness of the automated model will be tested using the dice similarity coefficient between manually segmentation regions and AI-based segments. For prognostication of gliomas, the next step will include feature extraction, which will consist of first-order (including shape, histogram), second-order or higher-order (e.g., different texture features like GLCM, GLDM, GLSZM, etc.), or deep learning techniques will be employed. Delta-radiomics will include temporal changes in the radiomic features from different time points for the same patient within the entire volume and individual regions. Subsequently, feature reduction and selection techniques like LASSO, recursive feature elimination will be used to shortlist the number of features depending on the sample size. The outputs will be decided based on the modeling defined for specific class problems (e.g., tumor vs. edema, recurrence vs. pseudo progression, outcomes, tumor region of interest vs. non-tumoral area) as obtained from the clinical information. Any class imbalance will be addressed using methods like random subset sampling or SMOTE analysis for data augmentation of the minority class. Machine learning algorithms like LDA, k-NN, SVM, random forest, AdaBoost, etc., will be applied singularly or in combination as an ensembled classifier to find the model with best performance. Deep learning classifiers will be used along with feature-based modeling and compared to test the classifier's applicability. Validation techniques like leave-one-out validation, k-fold validation, and split (into training and test cohort) will be used to assess the stability of the machine learning model. Radiomic analysis will be done by data scientist/ study investigators with expertise in data analytics. All segmentations will be done on open-source software like ITK snap (itksnap.org) or 3D Slicer (slicer.org). Feature extraction and modeling will be done using open-source software like Python (python.org). With continuous advancements in computational science, available newer analytical techniques and platforms will be applied as appropriate by collaborators from Indian Statistical Institute, Kolkata, Machine Intelligence Unit by sharing of the anonymized data.

Conditions
Glioma
Being tested
Radiomic analysis of imaging - MRI, PET, CT
Keywords
Glioma, Radiomics, Artificial Intelligence, Machine learning
Medical subject headings
Glioma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Radiomic analysis of imaging - MRI, PET, CTDiagnostic test

    Radiomic analysis of imaging will be undertaken as a standard of care to develop computational algorithms for patients treated in our institution.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Autosegmentation of tumor

    The correlation of tumor region between manual segmentation and artificial intelligence-based autosegmentation model will be assessed using the Dice coefficient of similarity.

    Measured: 3 years

  2. Prognostication of gliomas

    Radiomic signature in prognostication of gliomas with estimation of progression-free survival and overall survival using Kaplan Meier plots and radiomics score-based nomograms.

    Measured: 3 years

Secondary outcomes (2)
  1. Response assessment in gliomas

    Response assessment of gliomas using artificial intelligence model-based prediction and comparison with actual response (like radionecrosis, progression) using confusion matrices and estimation of parameters like sensitivity, specificity, accuracy, area under curve.

    Measured: 3 years

  2. Differentiation of glioma from non-glioma histology

    Use of radiomics model to differentiate gliomas from other brain tumors, with performance indices calculated using sensitivity, specificity, accuracy, area under curve.

    Measured: 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Sep 2023
  2. Study start15 Feb 2024
  3. Primary completionDec 2026 (estimated)
  4. Study completionDec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
1,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06036381
Sponsor's protocol ID
4146
Acronym
GLIO-RAD
Status last verified
Apr 2025
First submitted
28 Aug 2023
Last updated
9 Apr 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Glioma, run by Tata Memorial Centre at 1 site in India.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 9 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Dr. ARCHYA DASGUPTA, MD (022-24177000 ext. 6861, archya1010@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Autosegmentation of tumor (time frame: 3 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
GLIO-RAD Clinical Trial NCT06036381 | AzTrials